SlideShare uma empresa Scribd logo

Don’t Forget About MET: Keys to Detecting and Targeting MET Alterations as a Therapeutic Vulnerability in NSCLC

•Transferir como PPT, PDF•
•
PeerVoice
PeerVoice

Jonathan W. Goldman, MD, Xiuning Le, MD, PhD, and Diana N. Ionescu, MD, discuss NSCLC in this IME activity titled "Don’t Forget About MET: Keys to Detecting and Targeting MET Alterations as a Therapeutic Vulnerability in NSCLC." For the full presentation, please visit us at www.peervoice.com/HPP870.

Saúde e medicina
1 de 43
Don’t Forget About MET: Keys to Detecting and Targeting MET Alterations as a Therapeutic Vulnerability in NSCLC
Don’t Forget About MET: Keys to Detecting and Targeting MET Alterations as a Therapeutic Vulnerability in NSCLC
Don’t Forget About MET: Keys to Detecting and Targeting MET Alterations as a Therapeutic Vulnerability in NSCLC
Don’t Forget About MET: Keys to Detecting and Targeting MET Alterations as a Therapeutic Vulnerability in NSCLC
Don’t Forget About MET: Keys to Detecting and Targeting MET Alterations as a Therapeutic Vulnerability in NSCLC
Don’t Forget About MET: Keys to Detecting and Targeting MET Alterations as a Therapeutic Vulnerability in NSCLC
Don’t Forget About MET: Keys to Detecting and Targeting MET Alterations as a Therapeutic Vulnerability in NSCLC
Don’t Forget About MET: Keys to Detecting and Targeting MET Alterations as a Therapeutic Vulnerability in NSCLC
Don’t Forget About MET: Keys to Detecting and Targeting MET Alterations as a Therapeutic Vulnerability in NSCLC
Don’t Forget About MET: Keys to Detecting and Targeting MET Alterations as a Therapeutic Vulnerability in NSCLC
Don’t Forget About MET: Keys to Detecting and Targeting MET Alterations as a Therapeutic Vulnerability in NSCLC
Don’t Forget About MET: Keys to Detecting and Targeting MET Alterations as a Therapeutic Vulnerability in NSCLC
Don’t Forget About MET: Keys to Detecting and Targeting MET Alterations as a Therapeutic Vulnerability in NSCLC
Don’t Forget About MET: Keys to Detecting and Targeting MET Alterations as a Therapeutic Vulnerability in NSCLC
Don’t Forget About MET: Keys to Detecting and Targeting MET Alterations as a Therapeutic Vulnerability in NSCLC
Don’t Forget About MET: Keys to Detecting and Targeting MET Alterations as a Therapeutic Vulnerability in NSCLC
Don’t Forget About MET: Keys to Detecting and Targeting MET Alterations as a Therapeutic Vulnerability in NSCLC
Don’t Forget About MET: Keys to Detecting and Targeting MET Alterations as a Therapeutic Vulnerability in NSCLC
Don’t Forget About MET: Keys to Detecting and Targeting MET Alterations as a Therapeutic Vulnerability in NSCLC
Don’t Forget About MET: Keys to Detecting and Targeting MET Alterations as a Therapeutic Vulnerability in NSCLC
Don’t Forget About MET: Keys to Detecting and Targeting MET Alterations as a Therapeutic Vulnerability in NSCLC
Don’t Forget About MET: Keys to Detecting and Targeting MET Alterations as a Therapeutic Vulnerability in NSCLC
Don’t Forget About MET: Keys to Detecting and Targeting MET Alterations as a Therapeutic Vulnerability in NSCLC
Don’t Forget About MET: Keys to Detecting and Targeting MET Alterations as a Therapeutic Vulnerability in NSCLC
Don’t Forget About MET: Keys to Detecting and Targeting MET Alterations as a Therapeutic Vulnerability in NSCLC
Don’t Forget About MET: Keys to Detecting and Targeting MET Alterations as a Therapeutic Vulnerability in NSCLC
Don’t Forget About MET: Keys to Detecting and Targeting MET Alterations as a Therapeutic Vulnerability in NSCLC
Don’t Forget About MET: Keys to Detecting and Targeting MET Alterations as a Therapeutic Vulnerability in NSCLC
Don’t Forget About MET: Keys to Detecting and Targeting MET Alterations as a Therapeutic Vulnerability in NSCLC
Don’t Forget About MET: Keys to Detecting and Targeting MET Alterations as a Therapeutic Vulnerability in NSCLC
Don’t Forget About MET: Keys to Detecting and Targeting MET Alterations as a Therapeutic Vulnerability in NSCLC
Don’t Forget About MET: Keys to Detecting and Targeting MET Alterations as a Therapeutic Vulnerability in NSCLC
Don’t Forget About MET: Keys to Detecting and Targeting MET Alterations as a Therapeutic Vulnerability in NSCLC
Don’t Forget About MET: Keys to Detecting and Targeting MET Alterations as a Therapeutic Vulnerability in NSCLC
Don’t Forget About MET: Keys to Detecting and Targeting MET Alterations as a Therapeutic Vulnerability in NSCLC
Don’t Forget About MET: Keys to Detecting and Targeting MET Alterations as a Therapeutic Vulnerability in NSCLC
Don’t Forget About MET: Keys to Detecting and Targeting MET Alterations as a Therapeutic Vulnerability in NSCLC
Don’t Forget About MET: Keys to Detecting and Targeting MET Alterations as a Therapeutic Vulnerability in NSCLC
Don’t Forget About MET: Keys to Detecting and Targeting MET Alterations as a Therapeutic Vulnerability in NSCLC
Don’t Forget About MET: Keys to Detecting and Targeting MET Alterations as a Therapeutic Vulnerability in NSCLC
Don’t Forget About MET: Keys to Detecting and Targeting MET Alterations as a Therapeutic Vulnerability in NSCLC
Don’t Forget About MET: Keys to Detecting and Targeting MET Alterations as a Therapeutic Vulnerability in NSCLC
Don’t Forget About MET: Keys to Detecting and Targeting MET Alterations as a Therapeutic Vulnerability in NSCLC

Recomendados

The Central Role of the Pathologist in Detecting MET Alterations: Enabling Mu...
The Central Role of the Pathologist in Detecting MET Alterations: Enabling Mu...The Central Role of the Pathologist in Detecting MET Alterations: Enabling Mu...
The Central Role of the Pathologist in Detecting MET Alterations: Enabling Mu...
PeerVoice
 
Multiple Sclerosis and Bruton’s Tyrosine Kinase Inhibitors: Therapeutic Poten...
Multiple Sclerosis and Bruton’s Tyrosine Kinase Inhibitors: Therapeutic Poten...Multiple Sclerosis and Bruton’s Tyrosine Kinase Inhibitors: Therapeutic Poten...
Multiple Sclerosis and Bruton’s Tyrosine Kinase Inhibitors: Therapeutic Poten...
PeerVoice
 
Differentiating Between BTK Inhibitors in CLL: Same Class, Distinctly Dissimi...
Differentiating Between BTK Inhibitors in CLL: Same Class, Distinctly Dissimi...Differentiating Between BTK Inhibitors in CLL: Same Class, Distinctly Dissimi...
Differentiating Between BTK Inhibitors in CLL: Same Class, Distinctly Dissimi...
PeerVoice
 
A New Jigsaw Piece for Our Patient’s Puzzle: TROP2-Directed Therapy in HR+ Ad...
A New Jigsaw Piece for Our Patient’s Puzzle: TROP2-Directed Therapy in HR+ Ad...A New Jigsaw Piece for Our Patient’s Puzzle: TROP2-Directed Therapy in HR+ Ad...
A New Jigsaw Piece for Our Patient’s Puzzle: TROP2-Directed Therapy in HR+ Ad...
PeerVoice
 
Practical Considerations for FLT3 Inhibitors in Acute Myeloid Leukaemia: Opti...
Practical Considerations for FLT3 Inhibitors in Acute Myeloid Leukaemia: Opti...Practical Considerations for FLT3 Inhibitors in Acute Myeloid Leukaemia: Opti...
Practical Considerations for FLT3 Inhibitors in Acute Myeloid Leukaemia: Opti...
PeerVoice
 
Treating T2D in People of Younger Age in This Day and Age: How Would You Mana...
Treating T2D in People of Younger Age in This Day and Age: How Would You Mana...Treating T2D in People of Younger Age in This Day and Age: How Would You Mana...
Treating T2D in People of Younger Age in This Day and Age: How Would You Mana...
PeerVoice
 
Optimising Outcomes for Our Patients With Advanced Urothelial Carcinoma: Best...
Optimising Outcomes for Our Patients With Advanced Urothelial Carcinoma: Best...Optimising Outcomes for Our Patients With Advanced Urothelial Carcinoma: Best...
Optimising Outcomes for Our Patients With Advanced Urothelial Carcinoma: Best...
PeerVoice
 
The Quest for Optimal Haemolytic Control of Paroxysmal Nocturnal Haemoglobinuria
The Quest for Optimal Haemolytic Control of Paroxysmal Nocturnal HaemoglobinuriaThe Quest for Optimal Haemolytic Control of Paroxysmal Nocturnal Haemoglobinuria
The Quest for Optimal Haemolytic Control of Paroxysmal Nocturnal Haemoglobinuria
PeerVoice
 

Recomendados

The Central Role of the Pathologist in Detecting MET Alterations: Enabling Mu...
The Central Role of the Pathologist in Detecting MET Alterations: Enabling Mu...The Central Role of the Pathologist in Detecting MET Alterations: Enabling Mu...
The Central Role of the Pathologist in Detecting MET Alterations: Enabling Mu...
PeerVoice
 
Multiple Sclerosis and Bruton’s Tyrosine Kinase Inhibitors: Therapeutic Poten...
Multiple Sclerosis and Bruton’s Tyrosine Kinase Inhibitors: Therapeutic Poten...Multiple Sclerosis and Bruton’s Tyrosine Kinase Inhibitors: Therapeutic Poten...
Multiple Sclerosis and Bruton’s Tyrosine Kinase Inhibitors: Therapeutic Poten...
PeerVoice
 
Differentiating Between BTK Inhibitors in CLL: Same Class, Distinctly Dissimi...
Differentiating Between BTK Inhibitors in CLL: Same Class, Distinctly Dissimi...Differentiating Between BTK Inhibitors in CLL: Same Class, Distinctly Dissimi...
Differentiating Between BTK Inhibitors in CLL: Same Class, Distinctly Dissimi...
PeerVoice
 
A New Jigsaw Piece for Our Patient’s Puzzle: TROP2-Directed Therapy in HR+ Ad...
A New Jigsaw Piece for Our Patient’s Puzzle: TROP2-Directed Therapy in HR+ Ad...A New Jigsaw Piece for Our Patient’s Puzzle: TROP2-Directed Therapy in HR+ Ad...
A New Jigsaw Piece for Our Patient’s Puzzle: TROP2-Directed Therapy in HR+ Ad...
PeerVoice
 
Practical Considerations for FLT3 Inhibitors in Acute Myeloid Leukaemia: Opti...
Practical Considerations for FLT3 Inhibitors in Acute Myeloid Leukaemia: Opti...Practical Considerations for FLT3 Inhibitors in Acute Myeloid Leukaemia: Opti...
Practical Considerations for FLT3 Inhibitors in Acute Myeloid Leukaemia: Opti...
PeerVoice
 
Treating T2D in People of Younger Age in This Day and Age: How Would You Mana...
Treating T2D in People of Younger Age in This Day and Age: How Would You Mana...Treating T2D in People of Younger Age in This Day and Age: How Would You Mana...
Treating T2D in People of Younger Age in This Day and Age: How Would You Mana...
PeerVoice
 
Optimising Outcomes for Our Patients With Advanced Urothelial Carcinoma: Best...
Optimising Outcomes for Our Patients With Advanced Urothelial Carcinoma: Best...Optimising Outcomes for Our Patients With Advanced Urothelial Carcinoma: Best...
Optimising Outcomes for Our Patients With Advanced Urothelial Carcinoma: Best...
PeerVoice
 
The Quest for Optimal Haemolytic Control of Paroxysmal Nocturnal Haemoglobinuria
The Quest for Optimal Haemolytic Control of Paroxysmal Nocturnal HaemoglobinuriaThe Quest for Optimal Haemolytic Control of Paroxysmal Nocturnal Haemoglobinuria
The Quest for Optimal Haemolytic Control of Paroxysmal Nocturnal Haemoglobinuria
PeerVoice
 
When Blood Kills Babies: Identifying and Managing Severe Haemolytic Disease o...
When Blood Kills Babies: Identifying and Managing Severe Haemolytic Disease o...When Blood Kills Babies: Identifying and Managing Severe Haemolytic Disease o...
When Blood Kills Babies: Identifying and Managing Severe Haemolytic Disease o...
PeerVoice
 
CGA - Identify and Intervene: Optimising Care Pathways for Chronic Kidney Dis...
CGA - Identify and Intervene: Optimising Care Pathways for Chronic Kidney Dis...CGA - Identify and Intervene: Optimising Care Pathways for Chronic Kidney Dis...
CGA - Identify and Intervene: Optimising Care Pathways for Chronic Kidney Dis...
PeerVoice
 
Are You Forearmed When Managing Toxicities Associated With Chemoradiotherapy ...
Are You Forearmed When Managing Toxicities Associated With Chemoradiotherapy ...Are You Forearmed When Managing Toxicities Associated With Chemoradiotherapy ...
Are You Forearmed When Managing Toxicities Associated With Chemoradiotherapy ...
PeerVoice
 
Navigating Decisions With Limited Tools: A Review of Best Practices in Managi...
Navigating Decisions With Limited Tools: A Review of Best Practices in Managi...Navigating Decisions With Limited Tools: A Review of Best Practices in Managi...
Navigating Decisions With Limited Tools: A Review of Best Practices in Managi...
PeerVoice
 
Neuroimmunology Matters: A Specific Review of Emerging Targeted Strategies fo...
Neuroimmunology Matters: A Specific Review of Emerging Targeted Strategies fo...Neuroimmunology Matters: A Specific Review of Emerging Targeted Strategies fo...
Neuroimmunology Matters: A Specific Review of Emerging Targeted Strategies fo...
PeerVoice
 
Practical Perspectives and Straightforward Strategies for Optimising GDMT in ...
Practical Perspectives and Straightforward Strategies for Optimising GDMT in ...Practical Perspectives and Straightforward Strategies for Optimising GDMT in ...
Practical Perspectives and Straightforward Strategies for Optimising GDMT in ...
PeerVoice
 
MDT Management of Patients Receiving Radioligand Therapy: Strategies to Optim...
MDT Management of Patients Receiving Radioligand Therapy: Strategies to Optim...MDT Management of Patients Receiving Radioligand Therapy: Strategies to Optim...
MDT Management of Patients Receiving Radioligand Therapy: Strategies to Optim...
PeerVoice
 
Taking the Evidence from Paper to Practice: Shared Perspectives on Practical ...
Taking the Evidence from Paper to Practice: Shared Perspectives on Practical ...Taking the Evidence from Paper to Practice: Shared Perspectives on Practical ...
Taking the Evidence from Paper to Practice: Shared Perspectives on Practical ...
PeerVoice
 
Disruption at the Neuromuscular Junction: Relevance of Autoantibodies to Ther...
Disruption at the Neuromuscular Junction: Relevance of Autoantibodies to Ther...Disruption at the Neuromuscular Junction: Relevance of Autoantibodies to Ther...
Disruption at the Neuromuscular Junction: Relevance of Autoantibodies to Ther...
PeerVoice
 
The Science and the Art of Sequencing Therapies in Advanced CRC Beyond the Se...
The Science and the Art of Sequencing Therapies in Advanced CRC Beyond the Se...The Science and the Art of Sequencing Therapies in Advanced CRC Beyond the Se...
The Science and the Art of Sequencing Therapies in Advanced CRC Beyond the Se...
PeerVoice
 
Expert Lines of Thought in Sequencing Later Lines of Therapy in Advanced CRC
Expert Lines of Thought in Sequencing Later Lines of Therapy in Advanced CRCExpert Lines of Thought in Sequencing Later Lines of Therapy in Advanced CRC
Expert Lines of Thought in Sequencing Later Lines of Therapy in Advanced CRC
PeerVoice
 
The Case for Improved Care in COPD: Appreciating COPD as a Leading Cause of D...
The Case for Improved Care in COPD: Appreciating COPD as a Leading Cause of D...The Case for Improved Care in COPD: Appreciating COPD as a Leading Cause of D...
The Case for Improved Care in COPD: Appreciating COPD as a Leading Cause of D...
PeerVoice
 
TROP2-Directed Antibody-Drug Conjugates for Breast Cancer: The Clinical Signi...
TROP2-Directed Antibody-Drug Conjugates for Breast Cancer: The Clinical Signi...TROP2-Directed Antibody-Drug Conjugates for Breast Cancer: The Clinical Signi...
TROP2-Directed Antibody-Drug Conjugates for Breast Cancer: The Clinical Signi...
PeerVoice
 
Building a Better Approach to Obesity Care in Our Clinical Practices
Building a Better Approach to Obesity Care in Our Clinical PracticesBuilding a Better Approach to Obesity Care in Our Clinical Practices
Building a Better Approach to Obesity Care in Our Clinical Practices
PeerVoice
 
Catch Them Before They Fall: A Call to Action for Comprehensive Testing for H...
Catch Them Before They Fall: A Call to Action for Comprehensive Testing for H...Catch Them Before They Fall: A Call to Action for Comprehensive Testing for H...
Catch Them Before They Fall: A Call to Action for Comprehensive Testing for H...
PeerVoice
 
Radioligand Therapy and Therapeutic Sequencing in mCRPC
Radioligand Therapy and Therapeutic Sequencing in mCRPCRadioligand Therapy and Therapeutic Sequencing in mCRPC
Radioligand Therapy and Therapeutic Sequencing in mCRPC
PeerVoice
 
Multidisciplinary Perspectives on Advanced Management of CPF in CD: Exploring...
Multidisciplinary Perspectives on Advanced Management of CPF in CD: Exploring...Multidisciplinary Perspectives on Advanced Management of CPF in CD: Exploring...
Multidisciplinary Perspectives on Advanced Management of CPF in CD: Exploring...
PeerVoice
 
Approaching Airway Inflammation From Another Angle: The Rationale for Targeti...
Approaching Airway Inflammation From Another Angle: The Rationale for Targeti...Approaching Airway Inflammation From Another Angle: The Rationale for Targeti...
Approaching Airway Inflammation From Another Angle: The Rationale for Targeti...
PeerVoice
 
What’s New and What’s Next? Expanding Our Understanding of HCM in 2023
What’s New and What’s Next? Expanding Our Understanding of HCM in 2023What’s New and What’s Next? Expanding Our Understanding of HCM in 2023
What’s New and What’s Next? Expanding Our Understanding of HCM in 2023
PeerVoice
 
Adjusting Our Mindset and Our Approach: Patient and Provider Perspectives on ...
Adjusting Our Mindset and Our Approach: Patient and Provider Perspectives on ...Adjusting Our Mindset and Our Approach: Patient and Provider Perspectives on ...
Adjusting Our Mindset and Our Approach: Patient and Provider Perspectives on ...
PeerVoice
 
Scientificity and feasibility study of non-invasive central arterial pressure...
Scientificity and feasibility study of non-invasive central arterial pressure...Scientificity and feasibility study of non-invasive central arterial pressure...
Scientificity and feasibility study of non-invasive central arterial pressure...
Catherine Liao
 
BMK Glycidic Acid (sodium salt) CAS 5449-12-7 Pharmaceutical intermediates
BMK Glycidic Acid (sodium salt) CAS 5449-12-7 Pharmaceutical intermediatesBMK Glycidic Acid (sodium salt) CAS 5449-12-7 Pharmaceutical intermediates
BMK Glycidic Acid (sodium salt) CAS 5449-12-7 Pharmaceutical intermediates
dorademei
 

Mais conteúdo relacionado

Mais de PeerVoice

Mais de PeerVoice (20)

When Blood Kills Babies: Identifying and Managing Severe Haemolytic Disease o...
When Blood Kills Babies: Identifying and Managing Severe Haemolytic Disease o...When Blood Kills Babies: Identifying and Managing Severe Haemolytic Disease o...
When Blood Kills Babies: Identifying and Managing Severe Haemolytic Disease o...
 
CGA - Identify and Intervene: Optimising Care Pathways for Chronic Kidney Dis...
CGA - Identify and Intervene: Optimising Care Pathways for Chronic Kidney Dis...CGA - Identify and Intervene: Optimising Care Pathways for Chronic Kidney Dis...
CGA - Identify and Intervene: Optimising Care Pathways for Chronic Kidney Dis...
 
Are You Forearmed When Managing Toxicities Associated With Chemoradiotherapy ...
Are You Forearmed When Managing Toxicities Associated With Chemoradiotherapy ...Are You Forearmed When Managing Toxicities Associated With Chemoradiotherapy ...
Are You Forearmed When Managing Toxicities Associated With Chemoradiotherapy ...
 
Navigating Decisions With Limited Tools: A Review of Best Practices in Managi...
Navigating Decisions With Limited Tools: A Review of Best Practices in Managi...Navigating Decisions With Limited Tools: A Review of Best Practices in Managi...
Navigating Decisions With Limited Tools: A Review of Best Practices in Managi...
 
Neuroimmunology Matters: A Specific Review of Emerging Targeted Strategies fo...
Neuroimmunology Matters: A Specific Review of Emerging Targeted Strategies fo...Neuroimmunology Matters: A Specific Review of Emerging Targeted Strategies fo...
Neuroimmunology Matters: A Specific Review of Emerging Targeted Strategies fo...
 
Practical Perspectives and Straightforward Strategies for Optimising GDMT in ...
Practical Perspectives and Straightforward Strategies for Optimising GDMT in ...Practical Perspectives and Straightforward Strategies for Optimising GDMT in ...
Practical Perspectives and Straightforward Strategies for Optimising GDMT in ...
 
MDT Management of Patients Receiving Radioligand Therapy: Strategies to Optim...
MDT Management of Patients Receiving Radioligand Therapy: Strategies to Optim...MDT Management of Patients Receiving Radioligand Therapy: Strategies to Optim...
MDT Management of Patients Receiving Radioligand Therapy: Strategies to Optim...
 
Taking the Evidence from Paper to Practice: Shared Perspectives on Practical ...
Taking the Evidence from Paper to Practice: Shared Perspectives on Practical ...Taking the Evidence from Paper to Practice: Shared Perspectives on Practical ...
Taking the Evidence from Paper to Practice: Shared Perspectives on Practical ...
 
Disruption at the Neuromuscular Junction: Relevance of Autoantibodies to Ther...
Disruption at the Neuromuscular Junction: Relevance of Autoantibodies to Ther...Disruption at the Neuromuscular Junction: Relevance of Autoantibodies to Ther...
Disruption at the Neuromuscular Junction: Relevance of Autoantibodies to Ther...
 
The Science and the Art of Sequencing Therapies in Advanced CRC Beyond the Se...
The Science and the Art of Sequencing Therapies in Advanced CRC Beyond the Se...The Science and the Art of Sequencing Therapies in Advanced CRC Beyond the Se...
The Science and the Art of Sequencing Therapies in Advanced CRC Beyond the Se...
 
Expert Lines of Thought in Sequencing Later Lines of Therapy in Advanced CRC
Expert Lines of Thought in Sequencing Later Lines of Therapy in Advanced CRCExpert Lines of Thought in Sequencing Later Lines of Therapy in Advanced CRC
Expert Lines of Thought in Sequencing Later Lines of Therapy in Advanced CRC
 
The Case for Improved Care in COPD: Appreciating COPD as a Leading Cause of D...
The Case for Improved Care in COPD: Appreciating COPD as a Leading Cause of D...The Case for Improved Care in COPD: Appreciating COPD as a Leading Cause of D...
The Case for Improved Care in COPD: Appreciating COPD as a Leading Cause of D...
 
TROP2-Directed Antibody-Drug Conjugates for Breast Cancer: The Clinical Signi...
TROP2-Directed Antibody-Drug Conjugates for Breast Cancer: The Clinical Signi...TROP2-Directed Antibody-Drug Conjugates for Breast Cancer: The Clinical Signi...
TROP2-Directed Antibody-Drug Conjugates for Breast Cancer: The Clinical Signi...
 
Building a Better Approach to Obesity Care in Our Clinical Practices
Building a Better Approach to Obesity Care in Our Clinical PracticesBuilding a Better Approach to Obesity Care in Our Clinical Practices
Building a Better Approach to Obesity Care in Our Clinical Practices
 
Catch Them Before They Fall: A Call to Action for Comprehensive Testing for H...
Catch Them Before They Fall: A Call to Action for Comprehensive Testing for H...Catch Them Before They Fall: A Call to Action for Comprehensive Testing for H...
Catch Them Before They Fall: A Call to Action for Comprehensive Testing for H...
 
Radioligand Therapy and Therapeutic Sequencing in mCRPC
Radioligand Therapy and Therapeutic Sequencing in mCRPCRadioligand Therapy and Therapeutic Sequencing in mCRPC
Radioligand Therapy and Therapeutic Sequencing in mCRPC
 
Multidisciplinary Perspectives on Advanced Management of CPF in CD: Exploring...
Multidisciplinary Perspectives on Advanced Management of CPF in CD: Exploring...Multidisciplinary Perspectives on Advanced Management of CPF in CD: Exploring...
Multidisciplinary Perspectives on Advanced Management of CPF in CD: Exploring...
 
Approaching Airway Inflammation From Another Angle: The Rationale for Targeti...
Approaching Airway Inflammation From Another Angle: The Rationale for Targeti...Approaching Airway Inflammation From Another Angle: The Rationale for Targeti...
Approaching Airway Inflammation From Another Angle: The Rationale for Targeti...
 
What’s New and What’s Next? Expanding Our Understanding of HCM in 2023
What’s New and What’s Next? Expanding Our Understanding of HCM in 2023What’s New and What’s Next? Expanding Our Understanding of HCM in 2023
What’s New and What’s Next? Expanding Our Understanding of HCM in 2023
 
Adjusting Our Mindset and Our Approach: Patient and Provider Perspectives on ...
Adjusting Our Mindset and Our Approach: Patient and Provider Perspectives on ...Adjusting Our Mindset and Our Approach: Patient and Provider Perspectives on ...
Adjusting Our Mindset and Our Approach: Patient and Provider Perspectives on ...
 

Último

Introducing VarSeq Dx as a Medical Device in the European Union
Introducing VarSeq Dx as a Medical Device in the European UnionIntroducing VarSeq Dx as a Medical Device in the European Union
Introducing VarSeq Dx as a Medical Device in the European Union
Golden Helix
 
180-hour Power Capsules For Men In Ghana
180-hour Power Capsules For Men In Ghana180-hour Power Capsules For Men In Ghana
180-hour Power Capsules For Men In Ghana
healthwatchghana
 

Último (20)

Scientificity and feasibility study of non-invasive central arterial pressure...
Scientificity and feasibility study of non-invasive central arterial pressure...Scientificity and feasibility study of non-invasive central arterial pressure...
Scientificity and feasibility study of non-invasive central arterial pressure...
 
BMK Glycidic Acid (sodium salt) CAS 5449-12-7 Pharmaceutical intermediates
BMK Glycidic Acid (sodium salt) CAS 5449-12-7 Pharmaceutical intermediatesBMK Glycidic Acid (sodium salt) CAS 5449-12-7 Pharmaceutical intermediates
BMK Glycidic Acid (sodium salt) CAS 5449-12-7 Pharmaceutical intermediates
 
CURRENT HEALTH PROBLEMS AND ITS SOLUTION BY AYURVEDA.pptx
CURRENT HEALTH PROBLEMS AND ITS SOLUTION BY AYURVEDA.pptxCURRENT HEALTH PROBLEMS AND ITS SOLUTION BY AYURVEDA.pptx
CURRENT HEALTH PROBLEMS AND ITS SOLUTION BY AYURVEDA.pptx
 
PT MANAGEMENT OF URINARY INCONTINENCE.pptx
PT MANAGEMENT OF URINARY INCONTINENCE.pptxPT MANAGEMENT OF URINARY INCONTINENCE.pptx
PT MANAGEMENT OF URINARY INCONTINENCE.pptx
 
Anuman- An inference for helpful in diagnosis and treatment
Anuman- An inference for helpful in diagnosis and treatmentAnuman- An inference for helpful in diagnosis and treatment
Anuman- An inference for helpful in diagnosis and treatment
 
Aptopadesha Pramana / Pariksha: The Verbal Testimony
Aptopadesha Pramana / Pariksha: The Verbal TestimonyAptopadesha Pramana / Pariksha: The Verbal Testimony
Aptopadesha Pramana / Pariksha: The Verbal Testimony
 
Retinal consideration in cataract surgery
Retinal consideration in cataract surgeryRetinal consideration in cataract surgery
Retinal consideration in cataract surgery
 
A thorough review of supernormal conduction.pptx
A thorough review of supernormal conduction.pptxA thorough review of supernormal conduction.pptx
A thorough review of supernormal conduction.pptx
 
CNN-based plastic waste detection system
CNN-based plastic waste detection systemCNN-based plastic waste detection system
CNN-based plastic waste detection system
 
ANATOMY OF THE LOWER URINARY TRACT AND MALE [Autosaved] [Autosaved].pptx
ANATOMY OF THE LOWER URINARY TRACT AND MALE [Autosaved] [Autosaved].pptxANATOMY OF THE LOWER URINARY TRACT AND MALE [Autosaved] [Autosaved].pptx
ANATOMY OF THE LOWER URINARY TRACT AND MALE [Autosaved] [Autosaved].pptx
 
Introducing VarSeq Dx as a Medical Device in the European Union
Introducing VarSeq Dx as a Medical Device in the European UnionIntroducing VarSeq Dx as a Medical Device in the European Union
Introducing VarSeq Dx as a Medical Device in the European Union
 
World Hypertension Day 17th may 2024 ppt
World Hypertension Day 17th may 2024 pptWorld Hypertension Day 17th may 2024 ppt
World Hypertension Day 17th may 2024 ppt
 
In-service education (Nursing Mangement)
In-service education (Nursing Mangement)In-service education (Nursing Mangement)
In-service education (Nursing Mangement)
 
Cas 28578-16-7 PMK ethyl glycidate ( new PMK powder) best suppler
Cas 28578-16-7 PMK ethyl glycidate ( new PMK powder) best supplerCas 28578-16-7 PMK ethyl glycidate ( new PMK powder) best suppler
Cas 28578-16-7 PMK ethyl glycidate ( new PMK powder) best suppler
 
Book Trailer: PGMEE in a Nutshell (CEE MD/MS PG Entrance Examination)
Book Trailer: PGMEE in a Nutshell (CEE MD/MS PG Entrance Examination)Book Trailer: PGMEE in a Nutshell (CEE MD/MS PG Entrance Examination)
Book Trailer: PGMEE in a Nutshell (CEE MD/MS PG Entrance Examination)
 
180-hour Power Capsules For Men In Ghana
180-hour Power Capsules For Men In Ghana180-hour Power Capsules For Men In Ghana
180-hour Power Capsules For Men In Ghana
 
รายการตํารับยาแผนไทยแห่งชาติ ฉบับ พ.ศ. 2564.pdf
รายการตํารับยาแผนไทยแห่งชาติ ฉบับ พ.ศ. 2564.pdfรายการตํารับยาแผนไทยแห่งชาติ ฉบับ พ.ศ. 2564.pdf
รายการตํารับยาแผนไทยแห่งชาติ ฉบับ พ.ศ. 2564.pdf
 
Hemodialysis: Chapter 2, Extracorporeal Blood Circuit - Dr.Gawad
Hemodialysis: Chapter 2, Extracorporeal Blood Circuit - Dr.GawadHemodialysis: Chapter 2, Extracorporeal Blood Circuit - Dr.Gawad
Hemodialysis: Chapter 2, Extracorporeal Blood Circuit - Dr.Gawad
 
Relationship between vascular system disfunction, neurofluid flow and Alzheim...
Relationship between vascular system disfunction, neurofluid flow and Alzheim...Relationship between vascular system disfunction, neurofluid flow and Alzheim...
Relationship between vascular system disfunction, neurofluid flow and Alzheim...
 
Antiplatelets in IHD, Dose Duration, DAPT vs SAPT
Antiplatelets in IHD, Dose Duration, DAPT vs SAPTAntiplatelets in IHD, Dose Duration, DAPT vs SAPT
Antiplatelets in IHD, Dose Duration, DAPT vs SAPT